These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21569129)

  • 1. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
    Rudman SM; Josephs DH; Cambrook H; Karagiannis P; Gilbert AE; Dodev T; Hunt J; Koers A; Montes A; Taams L; Canevari S; Figini M; Blower PJ; Beavil AJ; Nicodemus CF; Corrigan C; Kaye SB; Nestle FO; Gould HJ; Spicer JF; Karagiannis SN
    Clin Exp Allergy; 2011 Oct; 41(10):1400-13. PubMed ID: 21569129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?
    Jensen-Jarolim E; Singer J
    Clin Exp Allergy; 2011 Oct; 41(10):1337-40. PubMed ID: 21545551
    [No Abstract]   [Full Text] [Related]  

  • 3. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors.
    Shiung YY; Chiang CY; Chen JB; Wu PC; Hung AF; Lu DC; Pan RL; Chang TW
    Immunobiology; 2012 Jul; 217(7):676-83. PubMed ID: 22226669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.
    Karagiannis SN; Bracher MG; Hunt J; McCloskey N; Beavil RL; Beavil AJ; Fear DJ; Thompson RG; East N; Burke F; Moore RJ; Dombrowicz DD; Balkwill FR; Gould HJ
    J Immunol; 2007 Sep; 179(5):2832-43. PubMed ID: 17709497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The soluble isoform of human FcɛRI is an endogenous inhibitor of IgE-mediated mast cell responses.
    Moñino-Romero S; Erkert L; Schmidthaler K; Diesner SC; Sallis BF; Pennington L; Jardetzky T; Oettgen HC; Bohle B; Fiebiger E; Szépfalusi Z
    Allergy; 2019 Feb; 74(2):236-245. PubMed ID: 30030936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
    Karagiannis SN; Wang Q; East N; Burke F; Riffard S; Bracher MG; Thompson RG; Durham SR; Schwartz LB; Balkwill FR; Gould HJ
    Eur J Immunol; 2003 Apr; 33(4):1030-40. PubMed ID: 12672069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: Diagnostic and therapeutic applications of rat basophilic leukemia cells.
    Rashid A; Sadroddiny E; Ye HT; Vratimos A; Sabban S; Carey E; Helm B
    Mol Immunol; 2012 Oct; 52(3-4):224-8. PubMed ID: 22750069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.
    Gould HJ; Mackay GA; Karagiannis SN; O'Toole CM; Marsh PJ; Daniel BE; Coney LR; Zurawski VR; Joseph M; Capron M; Gilbert M; Murphy GF; Korngold R
    Eur J Immunol; 1999 Nov; 29(11):3527-37. PubMed ID: 10556807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb.
    Wigginton SJ; Furtado PB; Armour KL; Clark MR; Robins A; Emara M; Ghaemmaghami AM; Sewell HF; Shakib F
    Clin Exp Allergy; 2008 Feb; 38(2):313-9. PubMed ID: 18070161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells.
    Luiten RM; Warnaar SO; Schuurman J; Pasmans SG; Latour S; Daëron M; Fleuren GJ; Litvinov SV
    Hum Antibodies; 1997; 8(4):169-80. PubMed ID: 9395919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
    Spicer J; Basu B; Montes A; Banerji U; Kristeleit R; Miller R; Veal GJ; Corrigan CJ; Till SJ; Figini M; Canevari S; Barton C; Jones P; Mellor S; Carroll S; Selkirk C; Nintos G; Kwatra V; Funingana IG; Doherty G; Gould HJ; Pellizzari G; Nakamura M; Ilieva KM; Khiabany A; Stavraka C; Chauhan J; Gillett C; Pinder S; Bax HJ; Josephs DH; Karagiannis SN
    Nat Commun; 2023 Jul; 14(1):4180. PubMed ID: 37491373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.
    Josephs DH; Nakamura M; Bax HJ; Dodev TS; Muirhead G; Saul L; Karagiannis P; Ilieva KM; Crescioli S; Gazinska P; Woodman N; Lombardelli C; Kareemaghay S; Selkirk C; Lentfer H; Barton C; Canevari S; Figini M; Downes N; Dombrowicz D; Corrigan CJ; Nestle FO; Jones PS; Gould HJ; Blower PJ; Tsoka S; Spicer JF; Karagiannis SN
    Allergy; 2018 Dec; 73(12):2328-2341. PubMed ID: 29654623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis.
    Josephs DH; Bax HJ; Lentfer H; Selkirk C; Spicer JF; Karagiannis SN
    Lancet; 2015 Feb; 385 Suppl 1():S53. PubMed ID: 26312875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting inhibitory Siglec-3 to suppress IgE-mediated human basophil degranulation.
    Barshow SM; Islam M; Commins S; Macauley MS; Paulson JC; Kulis MD
    J Allergy Clin Immunol; 2024 Aug; 154(2):492-497.e1. PubMed ID: 38593870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functions of dendritic-cell-bound IgE in allergy.
    Platzer B; Stout M; Fiebiger E
    Mol Immunol; 2015 Dec; 68(2 Pt A):116-9. PubMed ID: 26052071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid Stripping of Surface IgE Antibodies Bound to FcεRI is Unsuitable for the Functional Assays that Require Long-Term Culture of Basophils and Entire Removal of Surface IgE.
    Galeotti C; Karnam A; Das M; Kaveri SV; Bayry J
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31941161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge.
    Christensen LH; Holm J; Lund G; Riise E; Lund K
    J Allergy Clin Immunol; 2008 Aug; 122(2):298-304. PubMed ID: 18572230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome.
    Bax HJ; Chauhan J; Stavraka C; Khiabany A; Nakamura M; Pellizzari G; Ilieva KM; Lombardi S; Gould HJ; Corrigan CJ; Till SJ; Katugampola S; Jones PS; Barton C; Winship A; Ghosh S; Montes A; Josephs DH; Spicer JF; Karagiannis SN
    Cells; 2020 Jul; 9(7):. PubMed ID: 32645919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3.
    Okoshi Y; Tahara-Hanaoka S; Nakahashi C; Honda S; Miyamoto A; Kojima H; Nagasawa T; Shibuya K; Shibuya A
    Int Immunol; 2005 Jan; 17(1):65-72. PubMed ID: 15569773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Engineered Nanoparticles (ENPs) for the Study of High-Affinity IgE FcεRI Receptor Engagement and Rat Basophilic Leukemia (RBL) Cell Degranulation.
    Alelwani W; Alharbi RA; Wan D; Vllasaliu D; Falcone FH; Stolnik S
    Methods Mol Biol; 2020; 2163():171-180. PubMed ID: 32766975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.